Syros Pharmaceuticals (NASDAQ:SYRS) vs. Portage Biotech (NASDAQ:ATON) Head to Head Contrast

Portage Biotech (NASDAQ:ATON) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap manufacturing companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation.

Profitability

This table compares Portage Biotech and Syros Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Portage Biotech	N/A	N/A	N/A
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Portage Biotech and Syros Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Portage Biotech	1	0	1	0	2.00
Syros Pharmaceuticals	0	0	0	0	0.00

Portage Biotech presently has a consensus target price of $2.00, suggesting a potential upside of 502.41%. Given Portage Biotech’s stronger consensus rating and higher probable upside, equities analysts clearly believe Portage Biotech is more favorable than Syros Pharmaceuticals.

Volatility & Risk

Portage Biotech has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500.

Earnings & Valuation

This table compares Portage Biotech and Syros Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Portage Biotech	N/A	N/A	-$6.77 million	($8.18)	-0.04
Syros Pharmaceuticals	$386,000.00	0.03	-$164.57 million	($3.03)	0.00

Portage Biotech has higher earnings, but lower revenue than Syros Pharmaceuticals. Portage Biotech is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

13.4% of Portage Biotech shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

About Portage Biotech

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company’s product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.